BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23558378)

  • 1. Biological therapies for rheumatoid arthritis: progress to date.
    Malviya G; Salemi S; Laganà B; Diamanti AP; D'Amelio R; Signore A
    BioDrugs; 2013 Aug; 27(4):329-45. PubMed ID: 23558378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
    Gan EY; Chong WS; Tey HL
    BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
    Furfaro N
    J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of rheumatoid arthritis: Unraveling the conundrum.
    Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
    J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational agents for rheumatoid arthritis.
    Merkel PA; Letourneau EN; Polisson RP
    Rheum Dis Clin North Am; 1995 Aug; 21(3):779-96. PubMed ID: 8619099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
    Siddiqui MA
    Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitaxin applied molecular evolution.
    Mikecz K
    Curr Opin Investig Drugs; 2000 Oct; 1(2):199-203. PubMed ID: 11249574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction].
    Perniok A; Rubbert-Roth A
    Z Rheumatol; 2003 Oct; 62(5):433-8. PubMed ID: 14579030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of biologics in rheumatoid arthritis: where are we going?
    Pucino F; Harbus PT; Goldbach-Mansky R
    Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S19-41. PubMed ID: 16960244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.
    Strand V
    Z Rheumatol; 1998 Feb; 57(1):41-5. PubMed ID: 9566107
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel therapies for rheumatoid arthritis.
    Tremoulet AH; Albani S
    Expert Opin Investig Drugs; 2006 Nov; 15(11):1427-41. PubMed ID: 17040201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.
    June RR; Olsen NJ
    Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic approaches in rheumatoid arthritis.
    van Vollenhoven RF
    Presse Med; 2016 Jun; 45(6 Pt 2):e179-92. PubMed ID: 27242206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.
    Semerano L; Thiolat A; Minichiello E; Clavel G; Bessis N; Boissier MC
    Expert Opin Investig Drugs; 2014 Jul; 23(7):979-99. PubMed ID: 24766460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option.
    Abadoglu O; Epozturk K; Atayik E; Kaptanoglu E
    J Investig Allergol Clin Immunol; 2011; 21(4):319-21. PubMed ID: 21721382
    [No Abstract]   [Full Text] [Related]  

  • 19. [Targeting CD20 in rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The trials of anakinra.
    Burls A; Jobanputra P
    Lancet; 2004 Sep 4-10; 364(9437):827-8. PubMed ID: 15351176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.